LINC01555: A Long Intergenic Non-Protein-Coding RNA (G439927)

Target Name: LINC01555

NCBI ID: G439927

LINC01555

Other Name(s): long intergenic non-protein coding RNA 1555 | C1orf180 | Long intergenic non-protein coding RNA 1555

LINC01555: A Long Intergenic Non-Protein-Coding RNA

Non-coding RNAs (ncRNAs) have emerged as a promising candidate for drug targets and biomarkers due to their diverse functions and extensive gene regulation. Among them, long intergenic non-protein-coding RNAs (long non-protein-coding RNAs, lncRNAs) are particularly well-suited for drug targeting as they have been shown to play important roles in various biological processes and are involved in the development and progression of diseases. In this article, we will discuss LINC01555, a long non-protein-coding RNA that has potential as a drug target or biomarker.

LINC01555 is a 21.1-kb RNA molecule that is located between the intron-exon boundaries of genes 15 and 16 on chromosome 16. It is transcribed from the highly conserved promoter UTRG (UCAATTTG) in the nucleus and is expressed in various cell types of the human body.

Function and localization

LINC01555 is involved in the regulation of gene expression and has been shown to play a role in the development and progression of various diseases, including cancer. For example, LINC01555 has been associated with the regulation of the expression of the tumor suppressor gene TP53, which is often mutated in cancer cells. TP53 is a transcription factor that plays a critical role in maintaining genomic stability and is a target for many anti-cancer drugs.

In addition to its role in gene regulation, LINC01555 has also been shown to be involved in the regulation of protein translation, which is critical for the production of proteins that are involved in various cellular processes. This suggests that LINC01555 may be a potential drug target for diseases that are characterized by the overproduction or dysfunction of proteins.

Expression and regulation

LINC01555 is highly expressed in various tissues and cells of the human body, including the brain, heart, and gastrointestinal tract. It has been shown to be expressed in tissues that are critical for the development and progression of cancer, including the brain, which is a known hub for the regulation of cancer-related processes.

The regulation of LINC01555 expression is complex and involves multiple mechanisms. One of the known mechanisms is the interaction between LINC01555 and the transcription factor, TF-BP1. This interaction between LINC01555 and TF-BP1 has been shown to play a role in the regulation of gene expression and the expression of LINC01555 itself.

Another mechanism of LINC01555 regulation is the interaction between LINC01555 and the protein, heat shock factor 7 (HSF7). This interaction between LINC01555 and HSF7 has been shown to play a role in the regulation of gene expression and the expression of LINC01555 itself.

Drug targeting

The potential drug targeting of LINC01555 is based on its involvement in the regulation of gene expression and its association with various diseases. Several studies have shown that LINC01555 can be targeted with small molecules, including inhibitors of the protein, heat shock factor 7 (HSF7), which is a known interacting partner of LINC01555.

One of the most promising small molecules for targeting LINC01555 is a compound called UTRG-targeted small molecule inhibitor, which is a small molecule that binds to the protein, heat shock factor 7 (HSF7). This compound has been shown to inhibit the

Protein Name: Long Intergenic Non-protein Coding RNA 1555

The "LINC01555 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01555 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets